C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study
|
|
- Ruby Blair
- 5 years ago
- Views:
Transcription
1 Hemodialysis International 2009; ]]:1 7 once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study Michèle KESSLER, 1 Alberto MARTÍNEZ-CASTELAO, 2 Kostas C. SIAMOPOULOS, 3 Giuseppe VILLA, 4 Bruce SPINOWITZ, 5 Frank C. DOUGHERTY, 6 Ulrich BEYER 6 1 Department of Nephrology, University Hospital of Nancy, France; 2 University Hospital Bellvitge, Barcelona, Spain; 3 Department of Nephrology, University Hospital of Ioannina, Greece; 4 Division of Nephrology, Fondazione S. Maugeri, Pavia, Italy; 5 Division of Nephrology, New York Hospital Queens, Nephrology Associates, Flushing, NY, USA; 6 F. Hoffmann-La Roche Ltd, Basel, Switzerland Abstract, a continuous erythropoietin receptor activator is approved for the treatment of anemia in patients with chronic kidney disease (CKD). The ARCTOS (administration of in CKD patients to treat anemia with a twice-monthly schedule) phase 3 study demonstrated the efficacy and safety of in correcting anemia when administered once every 2 weeks (Q2W) subcutaneously in patients with CKD not on dialysis. We assessed the feasibility and long-term safety of converting patients who responded to treatment with Q2W to once every 4 weeks (Q4W) during a 24-week extension period. After the core ARCTOS study period (28 weeks), 296 patients entered the 24-week extension period. At week 29, patients who responded to Q2W during the core period were rerandomized to receive subcutaneous Q2W or Q4W. Patients in the comparator arm could receive darbepoetin alfa once weekly or Q2W. Dosage was adjusted to maintain hemoglobin (Hb) between 11 and 13 g/dl. Mean Hb levels remained stable in all groups, and were comparable at the end of the extension period (mean [standard deviation], Q2W, [0.90] g/dl; Q4W, [0.86] g/dl; darbepoetin alfa, [0.98] g/dl). Mean within-patient standard deviation values for Hb were also comparable in all groups (0.66, 0.62, and 0.65 g/dl for Q2W, Q4W and darbepoetin alfa, respectively). All treatments were well tolerated. Subcutaneous Q4W is safe and effective in maintaining stable Hb levels in patients with CKD not on dialysis following correction with subcutaneous Q2W. Key words: Anemia,, chronic kidney disease, hemoglobin INTRODUCTION Anemia is a common complication of chronic kidney disease (CKD) that results primarily from inadequate erythropoietin production by the damaged kidney. It develops early in the course of CKD, and is seen even among patients with Correspondence to: M. Kessler, Service de Néphrologie, Hôpitaux de Brabois, CHU de Nancy, rue du Morvan, Vandoeuvre les Nancy, France. m.kessler@chunancy.fr mild-to-moderate CKD (creatinine clearance 70 ml/min for men and 50 ml/min for women). 1 Recent estimates indicate that anemia is present in nearly half of all patients with CKD, increasing in prevalence and severity as kidney function deteriorates. 2 Anemia is associated with poor outcomes, and contributes to the increased morbidity and mortality associated with CKD. 3,4 The use of erythropoiesis-stimulating agents (ESAs) for the management of renal anemia ameliorates symptoms of anemia, is associated with improvements in quality of life and overall well-being 5 and possibly slows the decline of r 2009 The Authors. Journal compilation r 2009 International Society for Hemodialysis DOI: /j x 1
2 Kessler et al. renal function. 6 However, less than a third of patients with CKD who have anemia receive ESA treatment before they progress to end-stage renal disease The low usage of ESAs in patients who are not yet on dialysis may in part be attributed to the need for frequent dosing when short-acting ESAs such as epoetin are used. 11 Newer ESAs which can be dosed less frequently may improve the management of anemia in these patients., a continuous erythropoietin receptor activator, is approved for the treatment of anemia in patients with CKD. has a longer half-life than other ESAs (B130 hours following intravenous or subcutaneous administration), allowing extended dosing intervals of once every 2 weeks (Q2W) for anemia correction, and once monthly for maintenance treatment. 16 The ARCTOS (administration of in CKD patients to treat anemia with a twice-monthly schedule) study was designed to assess the efficacy of in correcting anemia in ESA-naïve patients with CKD not on dialysis. 17 The study demonstrated that given subcutaneously Q2W corrected anemia in these patients, with efficacy and safety similar to that of darbepoetin alfa. 17 We have analyzed the feasibility and long-term safety of converting those patients who responded to Q2W treatment in the ARCTOS study to once every 4 weeks (Q4W) during a 24-week extension phase. MATERIALS AND METHODS Study design and patients The rationale, design, and outcomes of the ARCTOS study have been published previously. 17 In brief, ARCTOS was an open-label, randomized, multicenter, darbepoetin alfacontrolled, parallel-group phase 3 study which examined the efficacy of Q2W for correcting anemia in patients with CKD not on dialysis. The study randomized 324 ESA-naïve patients (aged 18 years) with CKD stage 3 (creatinine clearance ml/min) or stage 4 (creatinine clearance ml/min) not on dialysis, adequate iron status (defined as serum ferritin 100 ng/ml or transferrin saturation 20% [or percentage of hypochromic red blood cells (RBCs) o10%]), and hemoglobin (Hb) 8 to 11 g/dl at baseline, to treatment with subcutaneous Q2W or subcutaneous darbepoetin alfa once weekly (QW) during an 18-week correction period followed by a 10-week evaluation period (core treatment period). Patients were excluded from the study if there was expected rapid progression of CKD (e.g., a creatinine clearance decrease of 420% within 12 weeks) or need for dialysis therapy within 6 months of the start of the study. If a patient required emergency or regular dialysis (hemodialysis or peritoneal dialysis) due to worsening renal function, the patient was to be kept in the study, where possible, until the final visit. Patients were also excluded if they had received ESA therapy within 12 weeks before screening, or if they had overt bleeding that necessitated transfusion within 8 weeks of the start of screening or during the screening period; C-reactive protein 415 mg/l; or life expectancy o12 months. At the end of the core treatment period (week 28), patients who responded to (defined as an increase in Hb 1.0 g/dl vs. baseline and Hb 11 g/dl without blood transfusion during the first 28 weeks after the first dose) were eligible to continue treatment, and were randomized at week 29 to receive subcutaneous either Q2W or Q4W for an additional 24-week extension period (weeks 29 53) to assess long-term safety. Patients who responded to darbepoetin alfa QW in the core period could receive darbepoetin alfa QW or Q2W during the extension period, at the discretion of the investigating nephrologists. Hemoglobin levels were to be maintained between 11 and 13 g/dl during the extension period. Dose adjustments were performed no more than Q4W, unless safety concerns dictated otherwise, as previously described. 17 Patients in the treatment group who remained on the Q2W schedule received the same dose as at week 27, and patients randomized to the Q4W schedule received a dose that was double the week 27 dose. Patients in the darbepoetin alfa group who remained on the QW schedule received the same dose as at week 28, and patients on the Q2W schedule received a dose that was double the week 28 dose. Assessments Patients were scheduled for assessments Q4W during the extension period. Hemoglobin, blood pressure, and heart rate were measured at each assessment and at the final visit, while iron parameters were assessed every 8 weeks and at the final visit. Anti- and antierythropoietin antibody testing was carried out at week 37 and at the final visit; other laboratory parameters were also assessed at these two visits. Adverse events (AEs), iron administration and RBC transfusions were recorded throughout the extension period. Data analysis Hemoglobin values over time were analyzed descriptively in the intent-to-treat (ITT [all patients randomized]) pop- 2 Hemodialysis International 2009; ]]:1 7
3 Q4W in patients not on dialysis ulation. Dose of study medication over time and the number of dose changes were analyzed descriptively in the safety population (all patients who received at least 1 dose of study medication and had a safety follow-up). In response to queries from Health Authorities, the proportion of patients maintaining stable Hb within 1 g/dl of the response value was analyzed in the ITT population. Within-patient variability of Hb, defined as the intraindividual standard deviation (SD) of Hb, was analyzed after week 36 in the ITT population. The incidence of RBC transfusions was also summarized and the groups compared using descriptive statistics. Group summary statistics were provided for safety parameters. RESULTS Patients Of the 324 patients randomly assigned to receive treatment during the 28-week core period ( Q2W, n =162; darbepoetin alfa QW, n = 162), 158 in the group and 156 in the darbepoetin alfa group responded to treatment (Figure 1). A total of 145 responders in the group were rerandomized to Q2W (73 patients) and Q4W (72 patients), including 1 patient in each group who received treatment for the extension period, but who withdrew before day 201 (defined as the cut-off for the start of the extension period). A total of 151 responders in the darbepoetin alfa group entered the extension period. Mean (SD) Hb levels were similar in both treatment groups at week 28, before patients were rerandomized ( Q2W, 12.2 [1.14] g/dl; darbepoetin alfa QW, 12.1 [1.11] g/dl). Iron parameters were also similar in both treatment groups at week 28 (median [interquartile range (IQR)] transferrin saturation,, Q2W, 27.7% [ ]; darbepoetin alfa QW, 24.0% [ ]: median [IQR] ferritin, Q2W, 223 ng/ml [ ]; darbepoetin alfa, 236 ng/ml [ ]). All 296 randomized patients who entered the extension period were eligible for the ITT and safety populations. In total, 275 patients completed the extension period ( Q2W, n = 68; Q4W, n =68; and darbepoetin alfa, n =139, Figure 1). Nineteen patients were withdrawn from the study during the extension treatment period: 4 patients in the Q2W group, 3 in the Q4W group, and 12 in the darbepoetin alfa group. Reasons for withdrawal were AE ( Q4W, n=1; darbepoetin alfa, n=4), death ( Q2W, n=2; Q4W, n=1; Figure 1 Progression of patients from core treatment period (correction and evaluation) to completion of the extension period. w One patient in each group was rerandomized to the extension period and received treatment at that time but withdrew before day 201, defined as the cut-off for the start of the extension period. =continuous erythropoietin receptor activator; QW=once weekly; Q2W =once every 2 weeks; Q4W=once every 4 weeks; R=randomization (core and extension periods). Hemodialysis International 2009; ]]:1 7 3
4 Kessler et al. Table 1 Demographic data for patients entering the extension period (intent-to-treat population) Q2W (n=73) Q4W (n=72) Darbepoetin alfa QW/Q2W (n=151) Male, n (%) 30 (41) 30 (42) 74 (49) Mean (SD) age 63.9 (13.8) 63.5 (14.9) 66.9 (12.8) (year) Race (%) Caucasian Black Oriental Other Ethnicity (%) Hispanic Non-Hispanic Geographic region (%) United States Outside United States =continuous erythropoietin receptor activator; QW=once weekly; Q2W=once every 2 weeks; Q4W=once every 4 weeks; SD=standard deviation. and darbepoetin alfa, n = 4), refusal of treatment ( Q2W, n =1; darbepoetin alfa, n =3), kidney transplantation (n=1 for Q2W and Q4W), and loss to follow-up (darbepoetin alfa, n =1). No patients were withdrawn due to lack of efficacy. Demographic data are summarized in Table 1. During the extension period, 109 patients (37%) received iron supplementation: 28 (38%) in the Q2W group, 26 (36%) in the Q4W group, and 55 (36%) in the darbepoetin alfa group. The most commonly received supplements were iron sucrose (14%, 15%, and 14% patients, respectively), ferrous sulfate (11%, 10%, and 11%, respectively), and ferrous gluconate (7%, 6%, and 5%, respectively). Most of the patients in each group had C-reactive protein levels 10 mg/l at the start of the extension period ( Q2W, 82%; Q4W, 90%; and darbepoetin alfa, 85.4%) and at the end of the extension period ( Q2W, 81%; Q4W, 79.3%; and darbepoetin alfa, 86.9%). Efficacy Table 2 shows that mean Hb levels remained stable in all treatment groups during the extension period. Mean Hb levels were maintained within 1 g/dl of the response value for 55 (76.4%) of the 72 patients given Q2W; 50 (70.4%) of the 71 patients given Q4W; and 103 (68.2%) of the 151 patients given darbepoetin alfa. Mean within-patient SD values for Hb were also comparable in all treatment groups (mean [SD] values, 0.66 [0.45] g/dl, 0.62 [0.41] g/dl, and 0.65 [0.42] g/dl for Q2W, Q4W, and darbepoetin alfa, respectively) (Figure 2). The numbers of patients receiving at least 1 RBC transfusion in the Q2W, Q4W, and darbepoetin alfa groups were 2 (2.7%), 0 (0%), and 4 (2.6%), respectively. Median doses of trial medication remained stable in all groups during the extension period (Table 3). Safety The incidence of AEs was similar in the 3 treatment groups: at least 1 AE was experienced by 67%, 64%, and 66% of patients in the Q2W, Q4W, and darbepoetin alfa groups, respectively. The most commonly reported AEs are listed in Table 4. Most were mild Table 2 Mean (SD) Hb during the extension period with and darbepoetin alfa (intent-to-treat population) n Q2W Q4W Darbepoetin alfa QW/Q2W Mean (SD) Hb (g/dl) n Mean (SD) Hb (g/dl) n Mean (SD) Hb (g/dl) Week (1.33) (1.08) (1.03) Week (1.33) (1.11) (1.00) Week (1.11) (1.05) (1.06) Week (1.03) (1.15) (1.08) Week (0.97) (0.96) (1.05) Week (0.90) (0.86) (0.98) =continuous erythropoietin receptor activator; Hb=hemoglobin; QW=once weekly; Q2W=once every 2 weeks; Q4W=once every 4 weeks; SD=standard deviation. 4 Hemodialysis International 2009; ]]:1 7
5 Q4W in patients not on dialysis no clinically relevant changes in vital signs or laboratory parameters during the study. Figure 2 Mean within-patient standard deviation (SD) of hemoglobin (Hb) after week 36 (intent-to-treat population) =continuous erythropoietin receptor activator; QW=once weekly; Q2W =once every 2 weeks; Q4W=once every 4 weeks. or moderate in intensity. Only 1 AE (chills: Q2W group) was considered to be related to study medication. The incidence of serious AEs was 15%, 15%, and 20% in the Q2W, Q4W, and darbepoetin alfa groups, respectively; none were considered to be treatment related. Nine patients died during the extension period: 2 in the Q2W group, 1 in the Q4W group, and 6 in the darbepoetin alfa group (including 1 patient who died after the end of the extension period [day 375], and 1 patient who chose to discontinue dialysis and continue with comfort care this patient died 8 days after last treatment). None of the deaths were considered to be treatment related. Iron parameters were well maintained in all treatment groups. No anti- antibodies were detected in any patient. One patient in the darbepoetin alfa group had nonneutralizing antierythropoietin antibodies. There were DISCUSSION The ARCTOS extension study has shown that subcutaneous Q4W effectively maintained Hb levels within a target range of 11 to 13 g/dl in patients with CKD not on dialysis following correction with subcutaneous Q2W. Furthermore, analysis of within-patient variability showed a similar degree of Hb control in all treatment groups. None of the patients in the Q4W group required transfusions. was also well tolerated, with an AE profile typical of this patient population. These data add to those of other phase 3 studies 18,19 by providing further evidence of the safety and efficacy of Q4W in patients with CKD. In the previously published maintenance studies, patients receiving epoetin once weekly to 3 times weekly (QW to TIW) were converted directly to Q4W. 18,19 The 2 studies, which were designed to demonstrate noninferiority of Q4W compared with epoetin QW to TIW, showed that Q4W maintained stable Hb levels as effectively as epoetin QW to TIW. 18,19 The present study demonstrates that patients can be converted from Q2W correction treatment to Q4W maintenance treatment without compromising efficacy or safety. The use of Q4W dosing regimens with other ESAs has been investigated in patients with CKD not on dialysis. Provenzano et al. 20 examined the efficacy of fixed doses of epoetin alfa given up to Q4W in patients who had previously received epoetin alfa. While the mean final Hb level in the Q4W group was statistically noninferior compared with the QW treatment group, the follow-up period in this study was short (16 weeks). In other studies, conversion of patients with CKD not on dialysis from Table 3 Median (IQR) weekly doses of trial medication per kg during the extension period (safety population) Q2W Q4W Darbepoetin alfa QW/Q2W Treatment (mg/kg/wk) n Median (IQR) n Median (IQR) n Median (IQR) Week ( ) ( ) ( ) Week ( ) ( ) ( ) Week ( ) ( ) ( ) Week ( ) ( ) ( ) Week ( ) ( ) ( ) Week ( ) ( ) ( ) Week ( ) ( ) ( ) =continuous erythropoietin receptor activator; IQR=interquartile range; QW=once weekly; Q2W=once every 2 weeks; Q4W=once every 4 weeks. Hemodialysis International 2009; ]]:1 7 5
6 Kessler et al. Table 4 Overall and most frequent adverse events (AEs) during the extension period (safety population) Q2W (n=73) % of patients with AE Q4W (n=72) Darbepoetin alfa QW/Q2W (n=151) Peripheral edema Renal impairment Dizziness Diarrhea Nasopharyngitis Urinary tract infection Arthralgia Hyperkalemia Hypertension Vomiting Back pain Nausea Cough Any AE Serious AE Death =continuous erythropoietin receptor activator; QW=once weekly; Q2W=once every 2 weeks; Q4W=once every 4 weeks. Q2W darbepoetin alfa maintenance dosing to Q4W darbepoetin alfa has been shown to be effective in selected patients; only those stable on Q2W maintenance dosing were converted to Q4W administration In 1 of the studies, 23 the efficacy criterion was less stringent (proportion of patients maintaining mean Hb 10 g/dl during the evaluation period [weeks 21 33]) than in the current study. Despite the adverse consequences of anemia on the well-being of the anemic patient, treatment remains inadequate in patients not yet on dialysis An obstacle to optimal anemia management in this patient group has been the need for frequent dosing of short-acting ESAs. A more convenient dosing regimen which does not compromise efficacy may improve patient compliance, and improved compliance may in turn help improve outcomes. With fewer clinic visits and fewer injections, less frequent ESA administration is not only preferred by patients with CKD not on dialysis over more frequent dosing, 24 but also has the potential to reduce health care resource utilization. In summary, the ARCTOS extension study demonstrates the efficacy and long-term safety of administered Q4W in patients with CKD not on dialysis following anemia correction with Q2W. Thus, has the potential to optimize anemia management in this patient group. ACKNOWLEDGMENTS ARCTOS extension study investigators: P. Altieri, M. Amato, A. Balducci, P. Barre, C. Breen, E. Brown, R. Burgos-Calderon, G. Carpenito, G. Choukroun, L. Craver, B. Culleton, F. De Alvaro, G. Deferrari, M. del Pino y Pino, G.-P. Dragoun, D. Durand, V. Esnault, P. Evenepoel, B. Faller, A. Fine, D. Fischer, M. Formica, U. Frei, L. Frenken, T. Golper, K. Hahn, K. Harris, E. Imbasciati, C. Jacquot, S. Jolly, G. Kaysen, P. Kerr, M. Kessler, N. Kopyt, C. Kovesdy, J. Kraut, J. Kwan, R. Lafayette, M. Laville, A. Levin, F. Locatelli, H. R. Locay, C. Lok, I. C. Macdougall, I. MacPhee, J. E. Marco Franco, A. Martinez Castelao, A. McMahon, E. Morales Ruiz, N. Muirhead, S. Murphy, P. C. Nader, G. M. Nassar, S. Noble, G. Papadakis, I. Papadakis, J. Penfield, V. Pichette, R. Provenzano, G. Pylypchuk, T. Risler, D. Rodriguez Puyol, S. Rosansky, G. Sakellariou, R. Schmidt, K. Siamopoulos, R. Solomon, B. Spinowitz, B. Stegmayr, M. Suranyi, P. Tam, S. Tobe, V. Vargemezis, C. Vela, G. Villa, R. Walker, K. Warr, C. Wijeyesinghe, C. Zoccali. This study was funded by F. Hoffmann-La Roche Ltd, Basel, Switzerland. Medical writing support was provided by Annete Njue-Doswell at Prime Medica Ltd, during the preparation of this paper, supported by F. Hoffmann-La Roche Ltd. Responsibility for opinions, conclusions, and interpretation of data lies with the authors. Manuscript received December 2008; revised August REFERENCES 1 Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: Results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol. 2002; 13: McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004; 20: Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996; 28: Levin A. Prevalence of cardiovascular damage in early renal disease. Nephrol Dial Transplant. 2001; 16(Suppl 2): Hemodialysis International 2009; ]]:1 7
7 Q4W in patients not on dialysis 5 Locatelli F, Aljama P, Bárány P, et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19(Suppl 2):ii1 ii47. 6 Gouva C, Nikolopoulos P, Ioannidis JPA, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int. 2004; 66: Obrador GT, Roberts T, St Peter WL, Frazier E, Pereira BJ, Collins AJ. Trends in anemia at initiation of dialysis in the United States. Kidney Int. 2001; 60: Valderrábano F, Hörl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP. Pre-dialysis survey on anemia management. Nephrol Dial Transplant. 2003; 18: McClellan WM, Jurkovitz C, Abramson J. The epidemiology and control of anemia among pre-esrd patients with chronic kidney disease. Eur J Clin Invest. 2005; 35(Suppl 3): US Renal Data System. Annual Data Report: Atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2007, p Pereira BJ. Overcoming barriers to the early detection and treatment of chronic kidney disease and improving outcomes for end-stage renal disease. Am J Manag Care. 2002; 8(Suppl):S122 S Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther. 1991; 50: Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999; 10: Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator () in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2006; 1: Padhi D, Ni L, Cooke B, Marino R, Jang G. An extended terminal half-life for darbepoetin alfa: Results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet. 2006; 45: MIRCERA s SPC (Summary of Product Characteristics). Section 4.2. Posology and Method of Administration. Available from: c/html/displaydoc.asp?documentid=19960 (accessed date: June 16, 2008). 17 Macdougall IC, Walker R, Provenzano R, et al, on behalf of the ARCTOS Study Investigators. corrects anemia in patients with chronic kidney disease not on dialysis: Results of a randomized clinical trial. Clin J Am Soc Nephrol. 2008; 3: Levin NW, Fishbane S, Valdés Cañedo F, et al, on behalf of the MAXIMA Study Investigators. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: A randomised non-inferiority trial (MAX- IMA). Lancet. 2007; 370: Sulowicz W, Locatelli F, Ryckelynck J-P, et al, on behalf of the PROTOS Study Investigators. Once-monthly subcutaneous maintains stable hemoglobin control in patients with chronic kidney disease on dialysis converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007; 2: Provenzano R, Bhaduri S, Singh AK. PROMPT Study Group. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clin Nephrol. 2005; 64: Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005; 63: Agarwal AK, Silver MR, Reed JE, et al. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis. J Intern Med. 2006; 260: Disney A, Jersey PD, Kirkland G, et al. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: A multicentre, open-label, Australian study. Nephrology (Carlton). 2007; 12: Hoggard J, Crouch T, McMurray S, et al. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis. Curr Med Res Opin. 2006; 22: Hemodialysis International 2009; ]]:1 7 7
Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationORIGINAL PAPER. Introduction
ORIGINAL PAPER Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study F. Dellanna, 1
More informationThe efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis
Nephrol Dial Transplant (2006) 21: 2846 2850 doi:10.1093/ndt/gfl387 Advance Access publication 5 August 2006 Original Article The efficacy of intravenous darbepoetin alfa administered once every 2 weeks
More informationDose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
Adv Ther (2013) 30:1007 1017 DOI 10.1007/s25-013-0063-y ORIGINAL RESEARCH Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study Peter Choi Mourad
More informationComparison of Usage and Effectiveness between Methoxy Polyethylene Glycol Epoetin Beta and Darbepoetin Alfa with Hemodialysis Patients
Journal of Pharmacy and Pharmacology 3 (2015) 182-190 doi: 10.17265/2328-2150/2015.04.004 D DAVID PUBLISHING Comparison of Usage and Effectiveness between Methoxy Polyethylene Glycol Epoetin Beta and Darbepoetin
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More informationK atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006
K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006 Why new guidelines? Rationale for KDOQI Anemia 2006 Expand scope to all
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationLVHN Scholarly Works. Lehigh Valley Health Network. Nelson Kopyt DO, FASN, FACP Lehigh Valley Health Network,
Lehigh Valley Health Network LVHN Scholarly Works Department of Medicine Efficacy and Safety of Oral Ferric Maltol (FM) in Treating Iron-Deficiency Anemia (IDA) in Patients with Chronic Kidney Disease
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin zeta, 1000 IU/0.3ml, 2000 IU/0.6ml, 3000 IU/0.9ml, 4000 IU/0.4ml, 5000 IU/0.5ml, 6000 IU/0.6ml, 8000 IU/0.8ml, 10,000 IU/1.0ml, 20,000 IU/0.5ml, 30,000 IU/0.75ml and
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Methoxy polyethylene glycol-epoetin beta (Mircera) Reference Number: CP.CPA.322 Effective Date: 06.01.18 Last Review Date: 05.18 Line of Business: Commercial Coding Implications Revision
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationMaintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study
original article http://www.kidney-international.org & 2008 International Society of Nephrology Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More informationF Dellanna, R Winkler, F Bozkurt, V Schettler, S Graf, N Bockreiss, D Fliser. HAL Id: hal https://hal.archives-ouvertes.
Dosing strategies for conversion of haemodialysis patients from short-acting erythropoiesis stimulating agents to once-monthly C.E.R.A.: experience from the MIRACEL study F Dellanna, R Winkler, F Bozkurt,
More informationIron Status in Chronic Renal Failure with Anemia
Chattagram Maa-O-Shishu Hospital Medical College Journal DOI: 10.11566/cmosh.2013.1201.12 Original Article Iron Status in Chronic Renal Failure with Anemia Shaheda Khanam 1 * Noorzahan Begum 2 AMM Ehteshamul
More informationA rationale for an individualized haemoglobin target
Nephrol Dial Transplant (2002) 17 [Suppl 6 ]: 2 7 A rationale for an individualized haemoglobin target Norman Muirhead University of Western Ontario, London, Ontario, Canada Abstract Despite the use of
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Centre for Clinical Practice
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice Review consultation document Review of Clinical Guideline (CG) CG 114: Anaemia management in Chronic Kidney Disease. Background
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (2000) 15 [Suppl 4]: 33 42 Nephrology Dialysis Transplantation European Best Practice Guidelines 9 13 Anaemia management Claude Jacobs, Walter H. Hörl, Iain C. Macdougall, Fernando
More informationIron metabolism anemia and beyond. Jacek Lange Perm, 8 October 2016
Iron metabolism anemia and beyond Jacek Lange Perm, 8 October 2016 1 Overview 1. Iron metabolism 2. CKD Chronic Kidney Disease 3. Iron deficiency beyond anemia and CKD 4. Conclusions 2 Why iron deficiency
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd
Resubmission ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharma UK Ltd 06 May 2011 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationScottish Medicines Consortium
Scottish Medicines Consortium epoetin theta, 1,000 IU/0.5mL, 2,000 IU/0.5mL, 3,000 IU/0.5mL, 4,000 IU/0.5mL, 5,000 IU/0.5mL, 10,000 IU/1mL, 20,000 IU/1mL, 30,000 IU/1mL solution for injection in pre filled
More informationYoung Ki Lee, Sung Gyun Kim, Jang Won Seo, Ji Eun Oh, Jong-Woo Yoon, Ja-Ryong Koo, Hyung Jik Kim and Jung Woo Noh
Nephrol Dial Transplant (2008) 23: 3240 3246 doi: 10.1093/ndt/gfn255 Advance Access publication 9 May 2008 Original Article A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationComparison of Pain and Efficacy of Darbepoetin Alfa and Epoetin Beta Pegol Treatment in Patients Receiving Peritoneal Dialysis
Original Comparison of Pain and Efficacy of Darbepoetin Alfa and Epoetin Beta Pegol Treatment in Patients Receiving Peritoneal Dialysis Tomoyuki Otsuka 1,YukinaoSakai 1,ShizukaYui 1, Masami Sukegawa 1,
More informationErythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
ORIGINAL ARTICLE Nephrology http://dx.doi.org/1.3346/jkms.216.31.1.55 J Korean Med Sci 216; 31: 55- Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease Sun
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationThe FIND-CKD Study Background Study design (Results)
The FIND-CKD Study Background Study design (Results) The FIND-CKD Study An open-label, multicentre, randomized, 3 arm study comparing the 12-month efficacy and safety of Ferric carboxymaltose (FCM, Ferinject
More informationMethoxy Polyethylene Glycol-Epoetin Beta
Drugs 2008; 68 (8): 1139-1156 ADIS DRUG EVALUATION 0012-6667/08/0008-1139/$53.45/0 2008 Adis Data Information BV. All rights reserved. Methoxy Polyethylene Glycol-Epoetin Beta A Review of its Use in the
More informationReticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial
Forni et al. BMC Nephrology 2013, 14:157 RESEARCH ARTICLE Open Access Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language
More informationNo Disclosures 03/20/2019. Learning Objectives. Renal Anemia: The Basics
Renal Anemia: The Basics Meredith Atkinson, M.D., M.H.S. Associate Professor of Pediatrics Johns Hopkins School of Medicine 16 March 2019 No Disclosures Learning Objectives At the end of this session the
More informationAnemia Update. Target Hb TREAT study Functional iron deficiency - Hepcidin Biosimilar epoetins
Anemia Update Peter Bárány Department of Renal Medicine/ Karolinska University Hospital and Division of Renal Medicine Department of Clinical Science, Intervention and Technology Karolinska Institutet,
More informationMIRCERA. INN: Methoxy polyethylene glycol-epoetin beta. Pre-filled syringe. Composition
MIRCERA INN: Methoxy polyethylene glycol-epoetin beta Pre-filled syringe Composition Single dose pre-filled syringes: containing 50µg, 75µg, 100µg, 150µg, 200µg, or 250µg methoxy polyethylene glycol-epoetin
More informationAnemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN
Anemia Management in Peritoneal Dialysis Patients Pranay Kathuria, FACP, FASN Professor of Medicine Director, Division of Nephrology and Hypertension University of Oklahoma College of Medicine Definition
More informationAnemia response to Methoxy
Open Access Journal of Clinical Nephrology Research Article Anemia response to Methoxy ISSN 2576-9529 Polyethylene Glycol-Epoetin Beta (Mircera) versus Epoetin Alfa (Eprex) in patients with chronic Kidney
More informationPublished Online 2013 July 24. Research Article
Nephro-Urology Monthly. 2013 September; 5(4):913-7. Published Online 2013 July 24. DOI: 10.5812/numonthly.12038 Research Article Comparative Study of Intravenous Iron Versus Intravenous Ascorbic Acid for
More informationCentocor Ortho Biotech Services, LLC
SYNOPSIS Issue Date: 17 June 2009 Name of Sponsor/Company Name of Finished Product PROCRIT Name of Active Ingredient(s) Protocol No.: PR04-15-001 Centocor Ortho Biotech Services, LLC Epoetin alfa Title
More informationStudy of Management of anemia in Chronic Kidney Disease Patients
Review Article Study of Management of anemia in Chronic Kidney Disease Patients Meby Susan Mathew, Nama Ravi Sneha Keerthi, Neelathahalli Kasturirangan Meera* Meera N.K, Visveswarapura Institute of Pharmaceutical
More informationEvaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases.
Evaluation of the effect of oral versus intravenous iron treatments on anemia in patients with chronic kidney diseases. Arif Sami Malik FICMS. Abstract Background:Correction of anemia as a result of renal
More informationAnaemia is a common. Original Article
20 Journal of the association of physicians of india march 2014 VOL. 62 Original Article A Single Arm, Prospective, Open Label, Multicentre Study for Evaluation of Efficacy and Safety of IV CERA for Treatment
More informationmean hemoglobin 11 g/dl (110 g/l) compared to patients with lower mean hemoglobin values (Table 20).
S44 Figure 53 depicts the trend in Epoetin dosing from the 1998 study period to the 2003 study period, with an increasing mean weekly Epoetin dose (units/kg/wk) for patients prescribed Epoetin in lower
More informationferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals
ferric carboxymaltose 50mg iron/ml solution for injection/infusion (Ferinject ) SMC No. (463/08) Vifor Pharmaceuticals 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationBecause of important technologic advances achieved over
Anemia and Heart Failure in Chronic Kidney Disease Francesco Locatelli, Pietro Pozzoni, and Lucia Del Vecchio Cardiovascular disease is mainly responsible for the poor long-term survival observed in chronic
More informationContinuous Erythropoietin Receptor Activator (Mircera ) for Renal Anemia
Issues in Emerging Health Technologies Continuous Erythropoietin Receptor Activator (Mircera ) for Renal Anemia Issue 113 February 2008 Summary Continuous erythropoietin receptor activator (CERA) is a
More informationPRE-dialysis survey on anaemia management
Nephrol Dial Transplant (2003) 18: 89 100 Original Article PRE-dialysis survey on anaemia management Fernando Valderrábano 1,y, Walter H. Hörl 2, Iain C. Macdougall 3,Jérôme Rossert 4, Boleslaw Rutkowski
More informationAranesp. Aranesp (darbepoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.01 Subject: Aranesp Page: 1 of 6 Last Review Date: September 15, 2017 Aranesp Description Aranesp
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationThe Changing Clinical Landscape of Anemia Management in Patients With CKD: An Update From San Diego Presentation 1
Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants
More informationAppropriateness of anemia management in hemodialysis patients
Saudi Pharmaceutical Journal (2012) 20, 85 91 King Saud University Saudi Pharmaceutical Journal www.ksu.edu.sa www.sciencedirect.com PRACTICE REPORT Appropriateness of anemia management in hemodialysis
More informationNephrology. Treatment of Anemia with Darbepoetin Alfa Administered de novo Once Every Other Week in Chronic Kidney Disease
American Journal of Nephrology Original Article: Patient-Oriented, Translational Research Am J Nephrol 2003;23:106 111 DOI: 10.1159/000068041 Received: July 23, 2002 Accepted: October 25, 2002 Treatment
More informationThe safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease
Kidney International, Vol. 64, Supplement 87 (2003), pp. S72 S77 The safety and efficacy of an accelerated iron sucrose dosing regimen in patients with chronic kidney disease DANIEL A. BLAUSTEIN, MICHAEL
More informationIN THE LAST few decades, several important
Anemia Management for Hemodialysis Patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) Guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) Findings Francesco Locatelli, MD, Ronald
More informationDrug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs)
Drug Class Prior Authorization Criteria Erythropoiesis Stimulating Agents (ESAs) Line of Business: Medicaid P & T Approval Date: May 16, 2018 Effective Date: July 1, 2018 This policy has been developed
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationAnemia is commonly associated with chronic kidney
Once-Monthly Subcutaneous C.E.R.A. Maintains Stable Hemoglobin Control in Patients with Chronic Kidney Disease on Dialysis and Converted Directly from Epoetin One to Three Times Weekly Wladyslaw Sulowicz,*
More informationTitle: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review
Title: Parenteral Iron Therapy for Anemia: A Clinical and Cost-Effectiveness Review Date: 14 February 2008 Context and policy issues: Anemia is a complication of chronic diseases and commonly occurs in
More informationRisk Factors in the Progression of Chronic Kidney Disease
Risk Factors in the Progression of Chronic Kidney Disease a report by Rainer Düsing Professor, Faculty of Medicine, University of Bonn DOI:10.17925/EE.2006.00.02.1e Chronic kidney disease (CKD) is a complex,
More informationSYNOPSIS CLINICAL STUDY REPORT
SYNOPSIS CLINICAL STUDY REPORT Non-interventional observational study on efficacy, safety and practicability of MIRCERA in kidney transplanted patients (BEAT) Report on non-interventional study ML21386
More informationThe use of surrogates as key performance indicators
REPLY The use of surrogates as key performance indicators Dr José Vinhas Department of Nephrology, Centro Hospitalar de Setúbal. Setúbal, Portugal Received for publication: 24/08/2012 Accepted: 31/08/2012
More informationAnemia is a common complication of chronic kidney
Original Articles Epoetin Alfa Once Every 2 Weeks Is Effective for Initiation of Treatment of Anemia of Chronic Kidney Disease Robert Benz,* Rebecca Schmidt, Kathleen Kelly, and Marsha Wolfson *Division
More informationABSTRACT ORIGINAL RESEARCH
Adv Ther (2014) 31:1155 1168 DOI 10.1007/s12325-014-0161-5 ORIGINAL RESEARCH Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationIron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Shaikh Zayed Hospital, Lahore
Proceeding S.Z.P.G.M.I. Vol: 29(2): pp. 83-87, 2015. Iron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Waqar Ahmad, Muhammad Rizwan Ul Haque, Abad Ur Rehman and Sammiullah
More informationInternational Journal of Current Research in Chemistry and Pharmaceutical Sciences Volume 1 Issue: Pages: 20-28
International Journal of Current Research in Chemistry and Pharmaceutical Sciences www.ijcrcps.com Volume 1 Issue: 3 2014 Pages: 20-28 (p-issn: 2348-5213; e-issn: 2348-5221) REVIEW ARTICLE PREVALENCE OF
More informationIron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia
Iron Supplementation and Erythropoiesis-Stimulatory Agents in the Treatment of Cancer Anemia Paolo Pedrazzoli, MD 1, Giovanni Rosti, MD 2, Simona Secondino, MD 1, and Salvatore Siena, MD 1 Unresponsiveness
More informationEfficacy and Safety of Methoxy Polyethylene Glycol Epoetin - Beta versus Epoetin Alpha for Treatment of. Chronic Renal Anemia in Hemodialysis Patients
American Journal of Pharmacological Sciences, 2015, Vol. 3, No. 4, 87-93 Available online at http://pubs.sciepub.com/ajps/3/4/1 Science and Education Publishing DOI:10.12691/ajps-3-4-1 Efficacy and Safety
More informationErythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS *
Erythropoiesis Stimulating Agents (ESAs): Epoetin Alfa * DIALYSIS * DESCRIPTION Erythropoietin is a glycoprotein produced in the kidneys responsible for the stimulation of red blood cell production. Epoetin
More informationTransfusion Burden among Patients with Chronic Kidney Disease and Anemia
Transfusion Burden among Patients with Chronic Kidney Disease and Anemia Elizabeth V. Lawler,* Brian D. Bradbury, Jennifer R. Fonda,* J. Michael Gaziano,* and David R. Gagnon* *Massachusetts Veterans Epidemiology
More informationEFFECTIVE SHARE CARE AGREEMENT
Specialist details Patient identifier Name: Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of Erythropoietin Stimulating Agent (ESA) Therapy (formerly known as EPO) for the correction of Anaemia
More informationRecombinant human epoetin beta in the treatment of renal anemia
REVIEW Recombinant human epoetin beta in the treatment of renal anemia Francesco Locatelli 1 Pietro Pozzoni 1 Lucia Del Vecchio 2 1 Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, Italy;
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationAnemia is very common among end-stage renal fail LATEST STRATEGY IN RENAL ANEMIA MANAGEMENT IN PERITONEAL DIALYSIS PATIENTS.
Proceedings of the 3rd Asian Chapter Meeting of the ISPD November 22 24, 2007, Hiroshima, Japan Peritoneal Dialysis International, Vol. 28 (2008), Supplement 3 0896-8608/08 $3.00 +.00 Copyright 2008 International
More informationSummary of Recommendation Statements Kidney International Supplements (2012) 2, ; doi: /kisup
http://www.kidney-international.org & 2012 KDIGO Summary of Recommendation Statements Kidney International Supplements (2012) 2, 283 287; doi:10.1038/kisup.2012.41 Chapter 1: Diagnosis and evaluation of
More informationEffective Health Care Program
Comparative Effectiveness Review Number 83 Effective Health Care Program Biomarkers for Assessing and Managing Iron Deficiency Anemia in Late-Stage Chronic Kidney Disease Executive Summary Background Chronic
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationWilliam E. Strauss *, Naomi V. Dahl, Zhu Li, Gloria Lau and Lee F. Allen
Strauss et al. BMC Hematology (2016) 16:20 DOI 10.1186/s12878-016-0060-x RESEARCH ARTICLE Open Access Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients
More informationIntravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University
Intravenous Iron: A Good Thing Made Better? Marilyn Telen, MD Wellcome Professor of Medicine Duke University Use of IV Iron There are increasing data regarding safety of IV iron. IV iron is superior to
More informationNew Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients
23. Berliner DialyseSeminar 1.-4. Dezember 2010 New Aspects to Optimize Epoetin Treatment with Intravenous Iron Therapy in Hemodialysis Patients George R. Aronoff, MD, MS, FACP Professor of Medicine and
More informationComparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care Hospital
Human Journals Research Article July 2017 Vol.:9, Issue: 4 All rights are reserved by Pournami A S et al. Comparison of Erythropoietin and Darbepoetin in Chronic Kidney Disease Patients in a Tertiary Care
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationMedical Policy. MP Erythropoiesis-Stimulating Agents
Medical Policy BCBSA Ref. Policy: 5.01.04 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Prescription Drug Related Policies 1.01.24 Interferential Current Stimulation 2.01.21 Temporomandibular
More informationFuture Direction of Anemia Management in ESRD. Jay B. Wish, MD 2008 Nephrology Update March 20, 2008
Future Direction of Anemia Management in ESRD Jay B. Wish, MD 2008 Nephrology Update March 20, 2008 The Evidence Normal Hct Study and CHOIR demonstrate adverse outcomes in ESA patients with target Hgb
More informationOriginal Article INTRODUCTION
Original Article The effect of Vitamin D administration on treatment of anemia in end-stage renal disease patients with Vitamin D deficiency on hemodialysis: A placebo-controlled, double-blind clinical
More informationPreoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD
Preoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD Preoperative anemia is common, especially in patients undergoing nonemergent high-blood-loss surgical
More informationLong-Acting Erythropoietin Stimulating Agents for Persistent Anemia After Kidney Transplant: Risk Factors and Outcome
ARTICLe Long-Acting Erythropoietin Stimulating Agents for Persistent Anemia After Kidney Transplant: Risk Factors and Outcome Torki Al-Otaibi, 1 Osama Gheith, 2 Medhat A. Halim, 1 Hasanein Abu Attia, 1
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Biochemical Targets. Calcium GUIDELINES
Date written: August 2005 Final submission: October 2005 Author: Carmel Hawley Biochemical Targets CARMEL HAWLEY (Woolloongabba, Queensland) GRAHAME ELDER (Westmead, New South Wales) Calcium GUIDELINES
More informationIntercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients
Clinical Nephrology, Vol. 71 No. 4/2009 (397-404) Intercurrent events and comorbid conditions influence hemoglobin level variability in dialysis patients Original 2009 Dustri-Verlag Dr. K. Feistle ISSN
More informationComparison between short- and long-acting erythropoiesisstimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome
Int Urol Nephrol (2014) 46:453 459 DOI 10.1007/s11255-013-0640-7 NEPHROLOGY - ORIGINAL PAPER Comparison between short- and long-acting erythropoiesisstimulating agents in hemodialysis patients: target
More informationErythropoietin Friend or Foe in Chronic Kidney Disease Anemia: An Analysis of Randomized Controlled Trials, Observational Studies and Meta-analyses
BJMP 2009:2(3) 12-20 Review Article Erythropoietin Friend or Foe in Chronic Kidney Disease Anemia: An Analysis of Randomized Controlled Trials, Observational Studies and Meta-analyses analyses Amir Hayat
More informationEPO e Ferro in Emodialisi: Il PBM al suo esordio. Lucia Del Vecchio. Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco
PATIENT BLOOD MANAGEMENT DALLA TEORIA ALLA PRATICA 16 FEBBRAIO 2018 EPO e Ferro in Emodialisi: Il PBM al suo esordio Lucia Del Vecchio Divisione di Nefrologia e Dialisi Ospedale A. Manzoni, ASST Lecco
More informationDrugs Used in Anemia
Drugs Used in Anemia Drugs of Anemia Anemia is defined as a below-normal plasma hemoglobin concentration resulting from: a decreased number of circulating red blood cells or an abnormally low total hemoglobin
More information